FBLN2 and breast cancer: In contrast, in the high grade breast cancer patient group (Grade III (P = 0.023; n = 458)) higher Fbln2 mRNA levels were significantly associated with a poorer outcome, and showed a statistically insignificant trend with poorer DMFS in patients with positive LN status (P = 0.14; n = 382).